Physician profile
Daniel Sundaresan Paul
NPI 1841266319
$243,510.26
in general payments reported to CMS, 2019-2025
40 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $19K · 2021: $49K · 2022: $61K · 2023: $38K · 2024: $55K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Travel and Lodging: $10K · Food and Beverage: $7,112 · Honoraria: $2,000 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,986.26 |
| Travel and Lodging | $10,123.61 |
| Food and Beverage | $7,112.29 |
| Honoraria | $2,000.00 |
| Education | $124.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $218,325.13 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Mylan Specialty L.P. | $12,085.15 | 2019-2024 | Yupelri |
| Viatris Specialty LLC | $4,524.70 | 2025 | Yupelri |
| Verona Pharma, INC. | $2,268.25 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals Lp | $1,881.42 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $971.67 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $499.40 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $377.83 | 2019-2025 | Dupixent |
| Baxter Healthcare | $339.57 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Actelion Pharmaceuticals US, INC. | $219.62 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Philips North America LLC | $216.15 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Insmed, INC. | $198.65 | 2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $187.32 | 2019-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $183.07 | 2019-2025 | Glassia |
| Genzyme Corporation | $159.54 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.